FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414504306> ?p ?o ?g. }

• W2414504306 abstract "Therapeutic resistance remains a major obstacle in metastatic colorectal cancer (mCRC) and biomarkers to guide treatment are essential to improving survival and quality of life in mCRC patients. A biopsy-driven prospective study was designed to identify biomarkers and mechanisms of resistance to a standard first-line therapy in patients with mCRC which could be useful in guiding treatment selection (QCROC-01; NCT00984048). We also hoped to recognize molecular changes over time, or resulting from the selection pressure of treatment, which could have implications for subsequent therapy. This study is ongoing and approved at thirteen sites with one-hundred patients enrolled so far. Patients with mCRC receiving FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) with bevacizumab consented to three needle core tumour biopsies at pre-treatment and at the time of resistance. The rate of both patient and physician acceptance of biopsies has steadily risen with time and experience. Serial bloods were also collected for proteomic analysis and circulating tumor DNA. Twenty-five biopsy samples were profiled using exome sequencing (tumor and germ line), RNAseq, low pass genome sequencing and miRNA analysis. Differential gene expression analysis revealed signatures associated with clinical response and resistance when comparing tumours obtained pre- and post-treatment. We detect changes in variant allele fraction including both depletion and enrichment of individual somatic mutations over the course of treatment, the latter of which may indicate subclonal and acquired “driver” mutations that confer therapeutic resistance. A small number of genes show recurrent evidence for changes in clonal enrichment at the time of relapse across multiple patients. These could also represent therapeutic targets for subsequent therapy for these patients, and as such, represent new treatment opportunities. Our findings provide insights into tumor evolution during first-line chemotherapy of mCRC that may hold clues to optimize current first-line therapeutic decision making and identifies potential target pathways for second-line stratification of patients. This study is part of the Canadian Colorectal Cancer Consortium which is a multi-site collaboration funded by the Terry Fox Research Institute and le fonds de recherche du quebec - sante. Citation Format: Suzan McNamara, Ryan Morin, Mathilde Couetoux du Tertre, Rosemary McCloskey, Rebecca Johnston, Daniel Fornika, Benoit Samson, Bernard Lesperance, Thierry Alcindor, Yoo-Joung Ko, Richard Dalfen, Eve St-Hilaire, Lucas Sideris, Felix Couture, Hans Prenen, Sabine Tejpar, Ronald Burkes, Andre Constantin, Errol Camlioglu, Adriana Aguilar, Adrian Gologan, Benoit Tetu, Celia M. Greenwood, Cyrla Hoffert, Samia Qureshi, Zuanel Diaz, Maud Marques, Micheal Witcher, Therese Gagnon-Kugler, Petr Kavan, Gerald Batist. Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: NCT00984048). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3888. doi:10.1158/1538-7445.AM2015-3888" @default.
• W2414504306 created "2016-06-24" @default.
• W2414504306 creator A5009190068 @default.
• W2414504306 creator A5010077476 @default.
• W2414504306 creator A5010372361 @default.
• W2414504306 creator A5010611898 @default.
• W2414504306 creator A5012005454 @default.
• W2414504306 creator A5012037815 @default.
• W2414504306 creator A5012339599 @default.
• W2414504306 creator A5015018859 @default.
• W2414504306 creator A5016700484 @default.
• W2414504306 creator A5016773298 @default.
• W2414504306 creator A5018567739 @default.
• W2414504306 creator A5023628228 @default.
• W2414504306 creator A5027182289 @default.
• W2414504306 creator A5029097581 @default.
• W2414504306 creator A5030976762 @default.
• W2414504306 creator A5031333036 @default.
• W2414504306 creator A5036712657 @default.
• W2414504306 creator A5042901839 @default.
• W2414504306 creator A5048707534 @default.
• W2414504306 creator A5055280080 @default.
• W2414504306 creator A5055324220 @default.
• W2414504306 creator A5057445007 @default.
• W2414504306 creator A5060176567 @default.
• W2414504306 creator A5063193415 @default.
• W2414504306 creator A5064806994 @default.
• W2414504306 creator A5067395665 @default.
• W2414504306 creator A5069070853 @default.
• W2414504306 creator A5075344723 @default.
• W2414504306 creator A5081644676 @default.
• W2414504306 creator A5082876118 @default.
• W2414504306 creator A5085440932 @default.
• W2414504306 date "2015-08-01" @default.
• W2414504306 modified "2023-09-27" @default.
• W2414504306 title "Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: NCT00984048)." @default.
• W2414504306 doi "https://doi.org/10.1158/1538-7445.am2015-3888" @default.
• W2414504306 hasPublicationYear "2015" @default.
• W2414504306 type Work @default.
• W2414504306 sameAs 2414504306 @default.
• W2414504306 citedByCount "0" @default.
• W2414504306 crossrefType "proceedings-article" @default.
• W2414504306 hasAuthorship W2414504306A5009190068 @default.
• W2414504306 hasAuthorship W2414504306A5010077476 @default.
• W2414504306 hasAuthorship W2414504306A5010372361 @default.
• W2414504306 hasAuthorship W2414504306A5010611898 @default.
• W2414504306 hasAuthorship W2414504306A5012005454 @default.
• W2414504306 hasAuthorship W2414504306A5012037815 @default.
• W2414504306 hasAuthorship W2414504306A5012339599 @default.
• W2414504306 hasAuthorship W2414504306A5015018859 @default.
• W2414504306 hasAuthorship W2414504306A5016700484 @default.
• W2414504306 hasAuthorship W2414504306A5016773298 @default.
• W2414504306 hasAuthorship W2414504306A5018567739 @default.
• W2414504306 hasAuthorship W2414504306A5023628228 @default.
• W2414504306 hasAuthorship W2414504306A5027182289 @default.
• W2414504306 hasAuthorship W2414504306A5029097581 @default.
• W2414504306 hasAuthorship W2414504306A5030976762 @default.
• W2414504306 hasAuthorship W2414504306A5031333036 @default.
• W2414504306 hasAuthorship W2414504306A5036712657 @default.
• W2414504306 hasAuthorship W2414504306A5042901839 @default.
• W2414504306 hasAuthorship W2414504306A5048707534 @default.
• W2414504306 hasAuthorship W2414504306A5055280080 @default.
• W2414504306 hasAuthorship W2414504306A5055324220 @default.
• W2414504306 hasAuthorship W2414504306A5057445007 @default.
• W2414504306 hasAuthorship W2414504306A5060176567 @default.
• W2414504306 hasAuthorship W2414504306A5063193415 @default.
• W2414504306 hasAuthorship W2414504306A5064806994 @default.
• W2414504306 hasAuthorship W2414504306A5067395665 @default.
• W2414504306 hasAuthorship W2414504306A5069070853 @default.
• W2414504306 hasAuthorship W2414504306A5075344723 @default.
• W2414504306 hasAuthorship W2414504306A5081644676 @default.
• W2414504306 hasAuthorship W2414504306A5082876118 @default.
• W2414504306 hasAuthorship W2414504306A5085440932 @default.
• W2414504306 hasConcept C113968399 @default.
• W2414504306 hasConcept C121608353 @default.
• W2414504306 hasConcept C126322002 @default.
• W2414504306 hasConcept C143998085 @default.
• W2414504306 hasConcept C2775934546 @default.
• W2414504306 hasConcept C2776694085 @default.
• W2414504306 hasConcept C2777802072 @default.
• W2414504306 hasConcept C2778260052 @default.
• W2414504306 hasConcept C2779529041 @default.
• W2414504306 hasConcept C2780962732 @default.
• W2414504306 hasConcept C2781187634 @default.
• W2414504306 hasConcept C526805850 @default.
• W2414504306 hasConcept C71924100 @default.
• W2414504306 hasConceptScore W2414504306C113968399 @default.
• W2414504306 hasConceptScore W2414504306C121608353 @default.
• W2414504306 hasConceptScore W2414504306C126322002 @default.
• W2414504306 hasConceptScore W2414504306C143998085 @default.
• W2414504306 hasConceptScore W2414504306C2775934546 @default.
• W2414504306 hasConceptScore W2414504306C2776694085 @default.
• W2414504306 hasConceptScore W2414504306C2777802072 @default.
• W2414504306 hasConceptScore W2414504306C2778260052 @default.
• W2414504306 hasConceptScore W2414504306C2779529041 @default.
• W2414504306 hasConceptScore W2414504306C2780962732 @default.
• W2414504306 hasConceptScore W2414504306C2781187634 @default.
• W2414504306 hasConceptScore W2414504306C526805850 @default.
• W2414504306 hasConceptScore W2414504306C71924100 @default.
• W2414504306 hasLocation W24145043061 @default.

• next